Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Intervalo de año de publicación
1.
Toxicol Appl Pharmacol ; 285(1): 61-70, 2015 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-25796170

RESUMEN

Insulin resistance is a characteristic feature of type 2 diabetes mellitus (T2DM) and is characterized by defects in insulin signaling. Protein tyrosine phosphatase 1B (PTP1B) is a key negative regulator of the insulin signaling pathways, and its increased activity and expression are implicated in the pathogenesis of insulin resistance. Therefore, the inhibition of PTP1B is anticipated to become a potential therapeutic strategy to treat T2DM. Fumosorinone (FU), a new natural product isolated from insect fungi Isaria fumosorosea, was found to inhibit PTP1B activity in our previous study. Herein, the effects of FU on insulin resistance and mechanism in vitro and in vivo were investigated. FU increased the insulin-provoked glucose uptake in insulin-resistant HepG2 cells, and also reduced blood glucose and lipid levels of type 2 diabetic KKAy mice. FU decreased the expression of PTP1B both in insulin-resistant HepG2 cells and in liver tissues of diabetic KKAy mice. Furthermore, FU increased the phosphorylation of IRß, IRS-2, Akt, GSK3ß and Erk1/2 in insulin-resistant HepG2 cells, as well as the phosphorylation of IRß, IRS-2, Akt in liver tissues of diabetic KKAy mice. These results showed that FU increased glucose uptake and improved insulin resistance by down-regulating the expression of PTP1B and activating the insulin signaling pathway, suggesting that it may possess antidiabetic properties.


Asunto(s)
Diabetes Mellitus/tratamiento farmacológico , Inhibidores Enzimáticos/farmacología , Ácidos Hidroxámicos/farmacología , Hipoglucemiantes/farmacología , Resistencia a la Insulina , Insulina/metabolismo , Hígado/efectos de los fármacos , Proteína Tirosina Fosfatasa no Receptora Tipo 1/antagonistas & inhibidores , Piridonas/farmacología , Transducción de Señal/efectos de los fármacos , Animales , Biomarcadores/sangre , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Diabetes Mellitus/sangre , Diabetes Mellitus/enzimología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Células Hep G2 , Humanos , Hígado/enzimología , Masculino , Ratones , Ratones Endogámicos C57BL , Fosforilación , Proteína Tirosina Fosfatasa no Receptora Tipo 1/metabolismo , Factores de Tiempo
2.
Data Brief ; 4: 159-61, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26217781

RESUMEN

This data article contains data related to the research article entitled "Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice" in the Toxicology and Applied Pharmacology [1]. Fumosorinone (FU) is a new inhibitor of protein phosphatase 1B inhibitor, which was isolated from insect pathogenic fungi Isaria fumosorosea. FU was found to inhibit PTP1B activity in our previous study [2]. PTP1B is the physiological antagonist of the insulin signalling pathway. Inhibition of PTP 1B may increase insulin sensitivity [3]. PTP1B has been considered promising as an insulin-sensitive drug target for the prevention and the treatment of insulin-based diseases [4]. We determined the effect of FU on the glucose consumption of IR HepG2 cells. FU caused significant enhancement in glucose consumption by insulin-resistant HepG2 cells compared with control cells.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA